Welcome to our dedicated page for SORRENTO THERAPEUTICS news (Ticker: SRNE), a resource for investors and traders seeking the latest updates and insights on SORRENTO THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SORRENTO THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SORRENTO THERAPEUTICS's position in the market.
Sorrento Therapeutics (Nasdaq: SRNE) announced positive preliminary results from two Phase 2 studies of Abivertinib in hospitalized COVID-19 patients. The studies identified a specific at-risk population: patients requiring oxygen support, showing significant improvements in avoiding death and respiratory failure. In the US trial, there was a 20% improvement (78.3% vs. 58.3%) in survival, while the Brazil study reported a 25% improvement (69.6% vs. 44.4%). Abivertinib has the potential to significantly reduce the progression of severe COVID-19 outcomes.
Sorrento Therapeutics (SRNE) announced positive preliminary results from two Phase 2 studies of Abivertinib, aimed at treating hospitalized COVID-19 patients with respiratory distress. The studies revealed a 20% reduction in death or respiratory failure at one month in the US study and 25% in Brazil. Patients in the US study were discharged from the ICU 2 days sooner. Abivertinib targets inflammation linked to acute respiratory distress syndrome, presenting a promising option for patients needing oxygen support. A pivotal Phase 3 trial is planned for further evaluation.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced that its rapid SARS-CoV-2 diagnostic test, COVISTIX, has received a CE Mark and marketing authorization from FAMHP, allowing its sale in territories accepting the Qarad EC-Rep CE Mark. COVISTIX, which provides results in approximately 15 minutes, has shown 81% sensitivity in studies, outperforming a leading rapid antigen test. Currently, EUA approvals are underway in Canada, Brazil, and the US. Sorrento is negotiating distribution deals to ensure rapid availability of the test across various markets.
Sorrento Therapeutics (SRNE) announced that its partner, Escugen Biotechnology, has received FDA authorization to initiate clinical trials for ESG-401, an anti-TROP-2 ADC with drug payload SN38. This investigational therapy aims to address significant unmet medical needs in treating multiple solid tumors, particularly triple-negative breast cancer and urothelial carcinoma. The approval is a pivotal step in Sorrento's commitment to developing innovative cancer therapies and highlights the company's ongoing efforts in the oncology domain.
Sorrento Therapeutics (NASDAQ: SRNE) announced FDA clearance to proceed with a global Phase 2 clinical study of resiniferatoxin (RTX) for treating intractable pain in advanced cancer patients. Supported by Phase 1 data showing RTX's safety and pain relief capabilities, the trial will evaluate three RTX doses against placebo controls in up to 120 patients. Initial results indicated a 30% decrease in pain scores for some subjects, highlighting RTX's potential as a non-opioid pain management solution.
Sorrento Therapeutics (NASDAQ: SRNE) announced Dr. Henry Ji's participation in the Benzinga Healthcare Small Cap Conference on September 29th. He will provide company updates at 11:30 AM ET and participate in a panel discussion at 12:35 PM EDT. The conference aims to gather small-cap healthcare companies and includes live presentations. Interested parties can register for free to attend the event. Sorrento is known for its development of therapies for cancer, pain, autoimmune diseases, and COVID-19, utilizing various innovative technologies.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced that Dr. Henry Ji, CEO, will participate in the Benzinga Healthcare Small Cap Conference on September 29, 2021. Dr. Ji is scheduled to provide company updates at 11:30 AM ET and join a panel discussion at 12:35 PM EDT. Interested participants can access the live event through a registration link. Sorrento is focused on developing innovative therapies for cancer, pain, autoimmune diseases, and COVID-19, emphasizing its commitment to enhance patient care through advanced treatments.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced its participation in the Cantor Virtual Healthcare Conference, scheduled for September 29, 2021, at 9:20 AM EST. Dr. Henry Ji, the Chairman and CEO, will present at the event. A live webcast of the presentation will be available through the company’s website, with a replay accessible for 14 days post-event. Sorrento is focused on developing innovative therapies for cancer, pain, autoimmune diseases, and COVID-19, supported by its immuno-oncology platforms and antiviral treatments.
Sorrento Therapeutics (SRNE) reported positive results for its COVID-19 diagnostic test, COVISTIX, with sensitivity at 81% in a study of 783 participants, compared to 62% sensitivity from the Panbio rapid antigen test in 2,202 participants. Specificity for COVISTIX was an impressive 96%. The findings suggest that COVISTIX can potentially offer fewer false negatives, crucial for managing COVID-19 transmission, especially among highly transmissible variants. This study, conducted by INMEGEN in Mexico, underscores Sorrento's commitment to developing effective diagnostic solutions.
Sorrento Therapeutics (Nasdaq: SRNE) announced Dr. Henry Ji's participation in the H.C. Wainwright 23rd Global Investment Conference, taking place virtually from September 13-15, 2021. The conference will cover updates on Sorrento's product pipeline focused on COVID-19, Cancer, and Autoimmune Therapeutics. Key highlights include the commercialization of COVISTIX in Mexico, Phase 2 trials for COVIDROPS and COVI-AMG, and ongoing studies in cancer therapeutics such as Abivertinib. An updated corporate presentation will be available on their website.
FAQ
What is the current stock price of SORRENTO THERAPEUTICS (SRNE)?
What is the market cap of SORRENTO THERAPEUTICS (SRNE)?
